BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients

Finviz2026/03/02 11:12

By:Finviz

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

On Friday, the U.S. Food and Drug Administration (FDA) approved BioMarin Pharmaceutical Inc.’s supplemental application for Palynziq (pegvaliase-pqpz), a treatment for phenylketonuria (PKU) in adolescents aged 12 and older.

FDA’s Expanded Approval

The FDA approved BioMarin’s supplemental Biologics License Application for Palynziq, making it the only enzyme substitution therapy approved for PKU management in pediatric patients aged 12 and older.

Phenylketonuria is a rare inherited disorder that causes an amino acid called phenylalanine (phe) to build up in the body.

The approval is based on the results from the Phase 3 PEGASUS study, which demonstrated statistically significant reductions in blood phenylalanine levels compared to diet alone.

Individuals in the Palynziq arm showed a significant mean reduction from baseline in blood Phe levels at Week 72 compared to those in the diet-only arm.

The company is also pursuing approval from the European Medicines Agency to expand treatment options for adolescents in the EU.

Technical Analysis

The stock is currently trading 4.5% below its 20-day simple moving average (SMA) and 8.2% below its 100-day SMA, indicating some short-term weakness. Over the past 12 months, shares have decreased by approximately 19%, and they are currently positioned closer to their 52-week lows than highs, reflecting a challenging market environment.

The RSI is at 50.00, suggesting a neutral position, while the MACD is at -0.10, below its signal line at 0.05, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum.

Key Resistance: $73.50
Key Support: $50.00

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $88.80. Recent analyst moves include:

Canaccord Genuity: Buy (Raises Target to $104.00) (Feb. 26)
Bernstein: Outperform (Raises Target to $94.00) (Feb. 25)
Guggenheim: Buy (Lowers Target to $86.00) (Feb. 25)

BMRN Price Action: BioMarin Pharmaceutical shares were down 3.92% at $59.30 during premarket trading on Monday.

Photo by Tada Images via Shutterstock

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

1. Markets diverged during the week. Between the October 23 and October 30 closes, BTC fell 4.78%, the Nasdaq 100 declined 1.98%, and gold and silver dropped 2.72% and 8.59%, respectively. The DAX, KOSPI, Nikkei 225 and Hang Seng advanced. We focus on differences in growth prospects, valuation sensitivity and risk exposures rather than applying a single directional view across assets. 2. Market reactions to Alphabet's and Intel's earnings brought returns on AI investment into focus. Attention is shifting from the scale of capital expenditure to revenue realization, margins and free cash flow. Lower interest rates can ease discount-rate pressure, but a sustained valuation recovery still requires support from both operating performance and financing conditions. 3. The November 3 US midterm elections and November 6 employment report are key events in the coming week. We monitor how post-election fiscal and legislative agendas may affect interest rates, the dollar and industry operating conditions. Our execution priorities are to manage leverage and concentration, retain margin and exit-liquidity buffers, and avoid treating a single political outcome as an automatic trading signal. 4. Following Binance's disclosure of a security incident, industry attention to endpoint protection, access segregation and coordinated incident response has increased. Key assets to monitor: BTC, the Nasdaq 100, crude oil and gold, alongside upcoming earnings from AAPL, AMD, PLTR, ARM, ANET and QCOM.

Bitget•2026/11/02 08:28